305 related articles for article (PubMed ID: 28766213)
1. Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk.
O'Leary E; Iacoboni D; Holle J; Michalski ST; Esplin ED; Yang S; Ouyang K
Ann Surg Oncol; 2017 Oct; 24(10):3060-3066. PubMed ID: 28766213
[TBL] [Abstract][Full Text] [Related]
2. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
3. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
4. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
5. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
6. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.
Frey MK; Kim SH; Bassett RY; Martineau J; Dalton E; Chern JY; Blank SV
Gynecol Oncol; 2015 Nov; 139(2):211-5. PubMed ID: 26296696
[TBL] [Abstract][Full Text] [Related]
7. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
[TBL] [Abstract][Full Text] [Related]
8. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Piccinin C; Panchal S; Watkins N; Kim RH
Expert Rev Anticancer Ther; 2019 Sep; 19(9):787-801. PubMed ID: 31469018
[No Abstract] [Full Text] [Related]
9. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.
Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW
J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792
[TBL] [Abstract][Full Text] [Related]
11. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
[TBL] [Abstract][Full Text] [Related]
12. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
14. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.
Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H
Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423
[TBL] [Abstract][Full Text] [Related]
15. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
Bernstein-Molho R; Friedman E; Kedar I; Laitman Y; Allweis TM; Gal-Yam EN; Feldman HB; Grinshpun A; Halpern N; Hartmajer S; Kadouri L; Katz LH; Kaufman B; Laish I; Levanon K; Philipsborn SL; Ludman M; Moran G; Peretz T; Reinstein E; Levi GR; Safra T; Shkedi S; Vinkler C; Levy Z; Goldberg Y
Breast Cancer Res Treat; 2020 Jun; 181(2):445-453. PubMed ID: 32303989
[TBL] [Abstract][Full Text] [Related]
17. Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories.
Rosenthal ET; Bernhisel R; Brown K; Kidd J; Manley S
Cancer Genet; 2017 Dec; 218-219():58-68. PubMed ID: 29153097
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
[TBL] [Abstract][Full Text] [Related]
19. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
